BHVI has a successful history of commercialising its technology through our comprehensive internal intellectual property program. The first product sale was in 1998 and products continue to be sold today.

Our success is twofold:

  1. We understand market needs and structure our research programs accordingly.
  2. We tailor our invention process to achieve commercial outcomes.

Our normal commercial pathways are below, however, we are open to other commercial opportunities:

1998

ALCON (Formerly CIBA Vision)

Co-development of Focus® Night & Day™ contact lens (first silicone hydrogels material)
1998

2002

CooperVision (Formerly OSI)

Co-development of Biomedics Toric soft contact lens

2002

2009

ALCON

Co-development of AIR OPTIX™ AQUA MULTIFOCAL contact lens

2009

2010

ZEISS

Co-development of MyoVision™ spectacle lens

2010

2017

Mark’ennovy

Licensed EDOF contact lens designs for myopia and presbyopia

SEED Co Ltd

Licensed EDOF contact lens designs for myopia and presbyopia

2017

2018

SynergEyes®

Licensed EDOF contact lens designs for myopia and presbyopia

2018

2019

OCULUS GMBH

Licensed predictive algorithm technology for refractive error management to be used in the Myopia Master® range of ophthalmic equipment

2019

2020

Bausch + Lomb

Exclusive global licensing agreement for myopia control contact lens

2020

Learn myopia management with BHVI.

So the next generation can keep

A myopia patient is a lifelong patient.

BHVI’s world leading Myopia Education Program brings you the latest research, clinical procedures, and business expertise.

For a limited time, take 30% off all courses! Use code: TAKE30

Copyright © Brien Holden Vision Institute (ABN 49 081 303 282) Brien Holden Vision Institute Foundation (ABN 86 081 872 586). All Rights Reserved.

Our site uses cookies. By continuing to use this website, you agree to their use. For more details, please check our Privacy Policy.